Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced that its executive management team will present at the H.C. Wainwright BioConnect 2022 Conference. The presentation will be available for on-demand listening starting January 10, 2022, at 7:00 a.m. ET on the Company’s website. Rockwell Medical focuses on improving treatment for iron deficiency and anemia, with its Ferric Pyrophosphate Citrate (FPC) technology platform aimed at various disease states. The Company has two FDA-approved therapies for hemodialysis patients and is expanding FPC for use outside of dialysis.

WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference.

The presentation will become publicly available for on-demand listening beginning on Monday, January 10 at 7:00 a.m. Eastern Time in the “Investors” section of the Company’s website at www.rockwellmed.com. A replay of the webcast will be archived on the Company’s website for 90 days.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com 

FAQ

When will Rockwell Medical present at the H.C. Wainwright BioConnect 2022 Conference?

Rockwell Medical will present at the H.C. Wainwright BioConnect 2022 Conference starting January 10, 2022, at 7:00 a.m. ET.

Where can I watch Rockwell Medical's presentation from the conference?

The presentation will be available for on-demand listening in the 'Investors' section of Rockwell Medical's website.

What is the focus of Rockwell Medical's FPC technology platform?

Rockwell Medical's FPC technology platform aims to provide transformative treatments for iron deficiency across various disease states.

Does Rockwell Medical have any FDA-approved therapies?

Yes, Rockwell Medical has two FDA-approved therapies indicated for patients undergoing hemodialysis.

What is the significance of Rockwell Medical's iron deficiency treatment?

Rockwell Medical's treatments aim to improve patient outcomes, reduce healthcare costs, and address iron deficiency in various settings.